Submit Your Feeds

Business News • PR NewsWire • NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occulsion (RVO), a Common Cause of Vision Loss

NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occulsion (RVO), a Common Cause of Vision Loss
NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occulsion (RVO), a Common Cause of Vision Loss

MARLOW, England, June 6, 2011 /PRNewswire/ -- Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX(R) (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusi

View More : http://www.prnewswire.com/news-releases/nice-recommends-ozurdexr-an-innovative-treatment-for-retinal-vein-occulsion-rvo-...
Releted News by prnewswire
Great Comebacks® Program Recognizes WOC Nurse Heidi H. Cross at WOCN 43rd Annual Conference
One in Three UK Wealthy Want More Financial Discipline
NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occulsion (RVO), a Common Cause of Vision Loss
Zhongpin Inc. Summarizes its Briefings and Discussions During its Tour of Factories Held on May 30 and 31, 2011
Home Sitemap Contact Us
© businessNewsNewsNews.com